Enantis

🎉Fantastic News!🎉 Enantis has been granted a US patent for its groundbreaking invention of FGF2-STAB®. This engineered protein is a true game-changer - it's a thermostable powerhouse 🌡️, boasting a mind-boggling stability that's 50-times greater than that of wild type FGF2.💪

🎉 Exciting News! 🎉 We are thrilled to announce that we have been granted a Canadian patent for our thermostable protein, FGF2-STAB®! A huge thanks to our talented scientists who made this possible. We're eager to maximize the impact of this game-changing invention.

Enantis have been granted the patent for FGF18-STAB® - our hyperstable fibroblast growth factor 18. Its pronounced biological response has potential in osteoarthritis treatment, and we are moving this molecule on the market as a pharmaceutical. enantis.com/pipeline/

Success story of our FireProt-ASR. Here, Pfizer successfully identified 57 ancestral ene reductases that function at high temperatures while maintaining their expression, solubility, and activity, making them useful for industrial processes. @pfizer_news. pubs.acs.org/doi/10.1021/ac…

FAO and WHO released this comprehensive report of food safety aspects of cell-based food. It's nice to see regulatory agencies, industries and research centers working together and paving the way to turn commercially available cultured meat into a reality. lnkd.in/dr9Zp23x

Our FGF2-STAB® has been given an interesting redo by Mateusz Krzyscik et al with high potential in regenerative and cancer medicine including wound healing, anticancer therapy (FGF2-STAB®-based drug carrier) and in diabetes (for patients that cannot be treated with insulin).

To start off 2021, we are happy to announce our successful grant application for TACR TREND „Technology Leaders“ programme! Our project was ranked the second one in life science category and 14th all together from the 434 applications. #post-1" target="_blank" rel="nofollow noopener">enantis.com/#post-1

After months of negotiations, we are delighted to announce that Enantis has entered into a global license agreement with one of the top providers of life science solutions with our innovative FGF2-STAB® molecule and its use in research and cell therapy market.

As a response to the recent coronavirus outbreak, Enantis joined the international efforts and became a member of FASTCURE consortium (fastcure.net). The goal of this initiative is to employ structural targeting of coronavirus using repurposing and better diagnostics.

PN Update: Improved gene expression in E. coli ph-nt.com/RPy2zD #Engenes #Biotech #Microbial

This year was full of new opportunities. We are licensing some of our products, developing new molecules and got the ISO certificate for quality. We are looking forward to the new challenges in 2020 and We Wish You a Lovely Christmas Time and a Happy New Year.

Are you attending #efib2019 next week? Our industrial partners from @enGenesBiotech and @Enantis wont miss it! Working together to boost the bioeconomy! ♻️ efibforum.com

We know, expressing that protein of interest can be a challenge! Keep calm and read this post with Juergen Mairhofer from @enGenesBiotech experts in protein expression! ow.ly/69L050wezGk

This fall, we have an extensive list of conferences to attend (lnkd.in/gzZ4cqU). The conference season has been kicked off by our Chief Scientific Officer, Radka Chaloupkova, who represented us at the Genetics of Industrial Microorganisms (GIM2019) held in Pisa, Italy.

The article summarizing the results of @Enantis’ SME Instrument @EU_H2020 project has been published on @CORDIS_EU website today: cordis.europa.eu/project/rcn/20…. This piece talks about our motivation to start the project, the results achieved and the experience gained during this period

Let's celebrate !!! @Enantis successfully finished SME Instrument Phase II @EU_H2020 grant. The firts sentence of the evaluation report is as follows: "Project has delivered exceptional results with significant immediate or potential impact" Isn't it great?

Today, we had a wonderful coaching session with Antonio Soarez here at Enantis. Antonio provided us with a lot of great insight into our business strategies and marketing, as well as accounting and long-term strategic plans. Thank you very much Antonio.

Our CEO Roman Badik has just presented @Enantis success story with the @H2020SME funding during the European Innovation Council Information Day. Great discussion and we are looking forward to future cooperation with all of the participating stakeholders to help Enantis grow.

@Enantis was invited to participate at the European Innovation Council Seminar. Our CEO, Roman Badik, will present our success story. If you are interested in attending, please, register at the following email address: comm-rep-cz-conference@ec.europa.eu. Invitation is attached.

Our colleague Radka Chaloupkova, Chief Scientific Officer of @Enantis, authored a scientific paper called Light-Emitting Dehalogenases: Reconstruction of Multifunctional Biocatalysts published in journal ACS Catalysis. pubs.acs.org/doi/abs/10.102… Well done, Radka! #protein